Impact of cancer immunotherapy on the kidneys
- Study HIC#:2000033212
- Last Updated:10/07/2024
The purpose is to evaluate the impact of immunotherapy on the kidneys. The overall goal of this project is to provide clinicians with non-invasive acute kidney injury (AKI) biomarkers in patients who develop kidney injury while on Immune Checkpoint Inhibitor (ICI) therapy and to understand the impact of early acute kidney injury (AKI)/acute interstitial nephritis (AIN) and other predictors on long-term chronic kidney disease risk in cancer survivors. Patients can access the study survey here: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_09xx6hfw9evWeTY
Contact Us
For more information about this study, including how to volunteer, contact:
Dennis Moledina
- Phone Number: 1-203-737-2782
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Eligibility Criteria:
- ≥18 years of age
- Receiving immunotherapy within the last year at Smilow Cancer Center
- At risk for, or experiencing kidney disease
